Masayoshi Okumi

Plain English
This study looked at a new method for improving the use of breast cancer biopsy samples by dividing them into two mirror-image sections. Researchers found that out of 72 samples with cancer, 70 (97.2%) showed consistent results when compared, meaning they provide reliable information for diagnosis. This is important because it allows for better testing and understanding of the cancer, which can lead to improved treatment options. Who this helps: This benefits patients and doctors by enabling more effective genetic testing and diagnosis of breast cancer.

Plain English
This study looked at DNA changes in prostate cancer to help determine how aggressive the cancer is. Researchers found that certain chemical markers on DNA, specifically near the C3orf37 gene, were much higher in high-grade prostate cancers compared to those that were less aggressive—higher levels were seen in 80% of high-grade cases. This is important because it could lead to better ways to diagnose and treat prostate cancer based on its severity. Who this helps: Patients with prostate cancer and their doctors.

Plain English
This study reports on a 41-year-old woman with a rare kidney condition called atypical hemolytic uremic syndrome (aHUS) who successfully received a kidney transplant from her mother. Despite facing complications like blood type incompatibility and previous blood transfusions that created antibody issues, she was treated with a drug called eculizumab and additional therapies to prepare her for the transplant. Following the procedure, she maintained stable kidney function without rejection or further complications over the next year. Who this helps: This benefits patients with aHUS and their families by providing hope for successful kidney transplants despite complex immunological challenges.

Plain English
This study focused on a 78-year-old man with bladder cancer who had previously received surgery and radiation for prostate cancer. Researchers used a robot-assisted procedure with ultrasound guidance to help carefully remove the bladder, ensuring safety and avoiding damage to nearby organs. The procedure was successful with no complications, demonstrating a safe approach for high-risk patients. Who this helps: This benefits patients with bladder cancer who have a complicated medical history.

Plain English
This study looked at how different factors affect the success of certain prostate cancer treatments in high-risk patients. Researchers analyzed data from 466 patients and found that those with a Gleason pattern of 5 and higher pretreatment levels of a specific enzyme (ALP) had lower survival rates. Importantly, patients with Gleason pattern 5 who were treated with apalutamide or enzalutamide lived longer than those who received abiraterone acetate. Who this helps: This helps doctors determine the best treatment options for patients with high-risk metastatic hormone-sensitive prostate cancer.

Plain English
This study looks at an unusual case where a man developed seminoma, a type of testicular cancer, 48 years after his testicle was removed. The cancer returned as a metastasis to a lymph node, and although he started chemotherapy, it was stopped due to side effects. Still, there was some positive response to the treatment, showing that even after many years, seminoma can come back, and doctors might need to adjust treatments for older patients based on their health. Who this helps: This helps doctors and patients understand the long-term risks of seminoma and how to manage treatment in older patients.

Plain English
This study looked at a 63-year-old woman who developed a pelvic mass after taking calcium polystyrene sulfonate, a medication used to lower high potassium levels. Doctors found an appendiceal abscess filled with crystals from this medication, but after treating her with antibiotics and draining the abscess, her condition improved. This is important because it highlights that while calcium polystyrene sulfonate can cause intestinal issues, it may also lead to rare complications like inflammatory pseudotumors, which can be treated effectively without surgery. Who this helps: This helps kidney transplant patients and their doctors.

Plain English
This study examined the use of MRI to assess tumor contact area in men with early-stage prostate cancer to see if it could predict whether cancer would extend beyond the prostate. Researchers analyzed data from 72 patients and found that 22.2% had cancer that had spread outside the prostate. They discovered that larger tumor contact areas on MRI were linked to a higher likelihood of cancer spreading and increased PSA recurrence after surgery, which emphasizes the importance of MRI in treatment planning. Who this helps: This helps doctors better assess cancer spread in prostate cancer patients and make informed decisions about treatment.

Plain English
This study looked at how carbon monoxide (CO), which is often considered poisonous, can actually help protect organs during the stressful process of transplantation. Researchers found that CO influences important pathways in the body that can reduce inflammation and cell death, potentially making transplants more successful. For instance, it helps keep blood vessels open and combats damaging responses after blood supply is restored to an organ. Understanding CO’s protective effects could lead to better treatments for organ transplant patients. Who this helps: This helps patients receiving organ transplants.

Plain English
This study looked at how different temperatures affect the preservation of pig kidneys after a period without blood flow. It found that kidneys preserved at 22 °C using a special solution had better function compared to those kept at the colder 4 °C. Specifically, the kidneys stored at 22 °C showed improved performance during testing and had less tissue damage after transplantation, while those preserved with a different solution did not survive longer than a week. Who this helps: This benefits patients needing kidney transplants by potentially improving the quality of donated organs.

Plain English
This study looked at the effects of inhaling argon gas on lung damage caused by temporarily blocking blood flow in miniature pigs. The results showed that pigs inhaling argon had better lung function two hours after the blood flow was restored, with a preserved blood gas ratio of 430 compared to just 272 in the control group. This is important because it suggests that argon could help protect lungs during procedures like transplants, potentially improving patient outcomes. Who this helps: Patients undergoing lung surgeries or organ transplants.

Plain English
This study focused on how to better diagnose and treat atypical haemolytic uraemic syndrome (aHUS) when other health issues, called "triggers," complicate the situation. Experts from several Asia-Pacific countries created step-by-step guides to help doctors identify aHUS quickly and provide the right treatment with specific drugs, called C5 inhibitors, to prevent serious damage to the kidneys and other organs. The study is essential because it offers clear recommendations for healthcare professionals to enhance patient care and outcomes in the presence of these triggers. Who this helps: This helps patients with aHUS and their doctors by providing clear guidelines for treatment.

Plain English
This study looked at men with high-risk localized prostate cancer who had a Gleason score of 6 or lower and received modern radiotherapy. Researchers followed 1,374 patients and found that those with a low Gleason score had a 5-year survival rate without cancer worsening of 97.8%, compared to 91.8% for those with higher Gleason scores. This is important because it shows that men with a Gleason score of 6 or lower may have better outcomes after treatment, possibly indicating they can be considered less risky than previously thought. Who this helps: Patients with high-risk prostate cancer and their doctors.

Plain English
This study reported on a 48-year-old man diagnosed with a rare type of bladder cancer called mucinous adenocarcinoma after experiencing blood in his urine. Imaging showed the cancer had spread to nearby lymph nodes, and after surgery to remove his bladder, he received a three-month course of chemotherapy with oxaliplatin and capecitabine. Eight months after the treatment, the patient had no signs of cancer returning, which is significant because there are no standard treatment guidelines for this uncommon cancer. Who this helps: This research benefits patients with rare types of bladder cancer and their doctors, offering insights into potential treatment options.

Plain English
This study looks at the rise of genitourinary cancers (like bladder and prostate cancer) in people who have received kidney transplants. Researchers found that these cancers are becoming more common among transplant recipients, with a notable increase making cancer a leading cause of death in kidney transplant patients in Japan. Understanding these trends and the specific risks can help improve how doctors manage the health of kidney transplant patients after their surgery. Who this helps: Patients who have received kidney transplants.

Plain English
This study looked at the long-term effects of a specific medication called prolonged-release tacrolimus in patients who received kidney transplants from living donors. After nearly 10 years, the study found that 7% of patients had kidney failures and 6.8% had died, highlighting that those with diabetes faced significantly higher risks—14% failure and 12.7% death rates compared to 5.4% for those without diabetes. This research is important because it provides valuable insights into how well this treatment works over a long period and identifies key risks for patients. Who this helps: This helps kidney transplant patients, especially those with diabetes.

Plain English
This study looked at how quickly cancer spreads in patients with advanced kidney cancer before they start treatment with nivolumab, a type of immune therapy. The researchers found that patients whose cancer grew more slowly (with a growth rate of less than 2.2 mm per month) lived longer and had better responses to treatment than those with faster-growing cancers. Specifically, patients with a high growth rate had more than twice the risk of their cancer worsening and over five times the risk of dying during the study period. Who this helps: This information benefits patients with metastatic renal cell carcinoma by helping doctors predict treatment outcomes based on cancer growth rates.

Plain English
This study looked at a condition called thrombotic microangiopathy (TMA) that can occur shortly after kidney transplants. Researchers found that out of 17 transplant recipients, all developed TMA within 72 hours of receiving their kidneys, and 16 of these cases involved mismatched blood types. The findings suggest that while some genetic factors related to TMA were identified in these patients, very few actually developed serious complications, highlighting the need for ongoing research to improve understanding and treatment. Who this helps: This helps kidney transplant recipients and their doctors by identifying risk factors and guiding future treatments.

Plain English
This study looked at the effects of new cancer treatments for patients with advanced bladder cancer in Japan, comparing results before and after these treatments became available. Researchers analyzed data from 158 patients and found that the average survival increased significantly from 14.5 months to 23.1 months after the new treatments were introduced. The five-year survival rate also rose from 7% to 36.3%, showing that these new therapies greatly improve outcomes for patients. Who this helps: This helps patients with metastatic urothelial carcinoma and their doctors.

Plain English
This study looked at how a specific signaling system in the body, called the FKN-CX3CR1 axis, influences the rejection of transplanted hearts when they suffer from damage due to a lack of blood supply followed by restoration (known as ischemia-reperfusion injury). Researchers found that in mice, hearts that were preserved poorly lasted only a short time before being rejected, while the presence of the FKN-CX3CR1 system made rejection happen more quickly. By blocking this signaling pathway, they were able to extend the survival of transplanted hearts, which means this approach could improve outcomes for heart transplant patients. Who this helps: Patients receiving heart transplants.

Plain English
This study looked at how well robot-assisted laparoscopic surgery worked for removing kidney tumors in young adults aged 18-39 compared to older adults. Researchers analyzed records from 1,023 patients and found that 67.6% of young adults successfully met all important recovery criteria, compared to 53.7% of older adults. The young adults also had better kidney function a year after the surgery, which is significant for their long-term health. Who this helps: This benefits young adult cancer patients and their doctors.

Plain English
This study focused on a 58-year-old man with advanced prostate cancer that had spread to his bladder and ureters, causing serious health issues. After going through hormone therapy, he underwent a surgery using robotic assistance, which successfully removed the cancer, and seven months later, his cancer markers were back to normal. This means that robot-assisted surgery combined with other treatments can effectively manage complex prostate cancer cases. Who this helps: This information benefits patients with advanced prostate cancer and their doctors.

Plain English
This study compared two surgical methods—transperitoneal (TP) and retroperitoneal (RP)—for removing lateral tumors from the kidney using robotic assistance. Researchers looked at outcomes from 96 patients (48 from each group) and found that the RP method led to quicker surgeries (124 minutes compared to 151 minutes), less blood loss (33 ml versus 52 ml), and shorter hospital stays (3.3 days against 4.0 days). These findings show that RP is often more efficient and beneficial for patients undergoing this type of kidney surgery. Who this helps: This benefits patients with lateral kidney tumors by offering a quicker and safer surgical option.

Plain English
This research studied the effectiveness of new criteria for diagnosing chronic active T cell-mediated rejection (CA-TCMR) in kidney transplant patients, using data from 406 patients who had a biopsy after one year. The study found that 8% of patients were diagnosed with CA-TCMR under the new guidelines, and this condition significantly increased the risk of serious complications, such as kidney failure or loss. Specifically, those diagnosed with CA-TCMR were over five times more likely to experience these severe outcomes compared to patients without the condition. Who this helps: This benefits kidney transplant patients and their doctors by improving the way potential rejection is diagnosed and managed.

Plain English
This study looked at how changes in treatment for metastatic renal cell carcinoma (a type of kidney cancer) affected survival rates in patients who had surgery to remove part of their kidney. Researchers analyzed 161 patients and found that those treated during the newer immune therapy era had a much longer average survival time compared to those treated with older therapies: around 32% survived in the early therapy period, while 46% survived in the late therapy period, and 21% in the immune therapy era. This improvement in survival highlights the importance of using the latest treatments for better outcomes. Who this helps: This information benefits kidney cancer patients and their doctors by guiding treatment decisions.

Plain English
This study looked at how a low dose of the immunosuppressant drug tacrolimus affects the development of new antibodies that can harm kidney transplants over seven years. Out of 584 kidney transplant recipients, 164 developed these harmful antibodies, but the researchers found that the levels of tacrolimus in the patients' blood did not relate to whether or not they developed these antibodies. Patients with more mismatched organ tissue and those who had existing antibodies before their transplant were more likely to face complications. Who this helps: This research benefits kidney transplant patients and doctors by highlighting factors that influence transplant success.

Plain English
This study looked at how the treatment outcomes for patients with advanced kidney cancer have changed over the past 40 years, focusing on different types of therapies. Researchers found that survival rates improved significantly with each new treatment era: patients lived a median of 13.1 months in the earliest group, which increased to 44.4 months in the era of targeted therapies, and continued to improve with immune checkpoint inhibitors. These findings are important because they highlight the effectiveness of newer treatments, showing that advancements in cancer therapies lead to longer survival for patients. Who this helps: This benefits patients with advanced kidney cancer and their healthcare providers.

Plain English
This research studied the risk of heart disease in patients who receive a kidney transplant from living donors. Researchers looked at data from 331 patients and found that 8.5% experienced heart disease after the transplant. They created a scoring system that helps predict who is at higher risk based on factors like age and health history, which proved to be quite accurate. Who this helps: This benefits patients who are considering kidney transplants and their doctors by allowing for better risk assessments and tailored care.

Plain English
This study details the case of a 67-year-old man diagnosed with prostate cancer that had spread to his lungs and bones. After receiving treatment for about five years, he developed swelling in both breasts, which was found to be due to cancer spreading from his prostate, not from breast cancer itself. This finding is significant as it highlights how prostate cancer can metastasize to areas like the breasts, which may not be well-recognized, helping doctors better understand and treat similar cases in the future. Who this helps: This helps patients and doctors in identifying and managing unusual cancer spread.

Plain English
This study looked at immune deposits in the kidneys of 1,894 patients and found that monoclonal deposits were present in 8.4% of native kidneys, compared to just 0.4% in the biopsies taken immediately after kidney transplants. Polyclonal deposits appeared more frequently in conditions like IgG4-related nephritis (37.5%) and diabetic nephropathy (31.3%). The findings indicate that while monoclonal IgG deposits are common, they don't seem to harm kidney function, which can help doctors understand these deposits better and guide future research. Who this helps: This helps patients with kidney diseases and doctors managing their care.

Plain English
This study looked at the AST/ALT ratio, which is a blood test result, in patients with kidney cancer who also have end-stage kidney disease. It found that patients with a higher AST/ALT ratio (1.42 or more) had a significantly lower chance of surviving for ten years after surgery—only 64.3% survived compared to 87.2% for those with a lower ratio. This is important because it helps doctors identify which patients are at higher risk and might need more intensive care after their surgery. Who this helps: This helps patients with end-stage kidney disease and their doctors by improving treatment planning and outcomes.

Plain English
This study looked at factors that could predict if kidney cancer would come back after surgery in 1,227 patients with early-stage tumors. Researchers found that 3.2% of patients experienced a recurrence, with the strongest risk factors being high-grade tumors and those that were upgraded to a more severe stage after surgery. This matters because it helps doctors identify which patients need closer follow-up after surgery to catch any potential recurrence early. Who this helps: This helps patients with high-grade kidney tumors and their doctors.

Plain English
This study looked at the outcomes of repeat partial nephrectomy (RePN) compared to the first time a partial nephrectomy (iPN) was done in patients with kidney cancer in a single kidney. Out of 79 patients, 11 had RePN, and while their tumors were smaller, the surgery took longer, and they lost more blood compared to the iPN group. However, both groups had similar rates of complications and kidney function after surgery, showing that RePN is safe and effective for these patients. Who this helps: Patients with kidney cancer who have had surgery in one kidney.

Plain English
This study looked at a kidney transplant recipient who developed bladder cancer and needed a complicated surgery called radical cystectomy, where the bladder is removed. The surgery was performed using a robot-assisted technique, which helped the doctors navigate the patient's unusual urinary tract setup. Despite facing some postoperative complications, the patient recovered well, highlighting that robot-assisted surgery can be beneficial for patients with complicated medical histories. Who this helps: This helps kidney transplant recipients who develop bladder cancer.

Plain English
This study focused on how to treat children with autosomal recessive polycystic kidney disease (ARPKD) who also have end-stage renal disease (ESRD) and related liver issues. Researchers treated seven children using personalized strategies based on their liver conditions, resulting in successful outcomes: two received a liver-kidney transplant, four had their spleens removed followed by kidney transplants, and one underwent just a kidney transplant. No severe complications occurred during the follow-up period of about 6 years, with kidney function remaining stable for all patients. Who this helps: This benefits children with ARPKD and their families by providing tailored treatment options.

Plain English
This study looked at patients with metastatic renal cell carcinoma (mRCC) who had surgery to remove all visible cancer, called complete metastasectomy. Among 51 patients, 39 (74%) had their cancer come back, with a median time without recurrence of just 22 months. The research found that patients with two or more metastatic sites or specific tumor characteristics called sarcomatoid features were at a higher risk of recurrence and should be closely monitored even after surgery. Who this helps: This information benefits patients and doctors in planning ongoing care after surgery for metastatic renal cell carcinoma.

Plain English
This study looked at how arteriosclerosis, a condition in which blood vessels become thickened, affects the outcomes of kidney transplants from living donors. Researchers compared over 1,300 kidney transplant cases and found that while the long-term survival rates of the transplanted kidneys were similar in both groups—those with and without arteriosclerosis—patients receiving kidneys with arteriosclerosis had a 26% higher rate of overall rejection and experienced worse kidney function after the transplant. This matters because it highlights the need for careful monitoring of patients and donors when arteriosclerosis is present in donor kidneys, as it could lead to more complications. Who this helps: This information aids kidney transplant patients, their doctors, and living kidney donors.

Plain English
Researchers studied the impact of muscle loss, known as sarcopenia, on the survival of 197 men with metastatic hormone-sensitive prostate cancer. They found that 82.7% of these men had sarcopenia, and those with the condition lived significantly shorter lives: the average cancer-specific survival was 77 months for sarcopenic patients, compared to not reached for those without sarcopenia. This research is important because it shows that sarcopenia is a serious risk factor for survival in these patients, particularly for younger men under 73. Who this helps: This helps patients and doctors by identifying sarcopenia as a crucial factor to consider in treatment plans.

Plain English
This study looked at how effective axitinib is for patients with metastatic kidney cancer (mRCC) who didn’t respond to another treatment called nivolumab. Among the 17 patients treated, almost half (47.1%) experienced disease progression, but 29.4% had some level of response to axitinib, and the average time before the cancer worsened was about 12.8 months. This matters because it offers hope for new treatment options for patients who didn’t benefit from earlier therapies. Who this helps: This helps patients with metastatic renal cell carcinoma who have not responded to previous treatments.

Plain English
This study looked at how intravenous immunoglobulin (Ig) therapy affects kidney transplant rejection caused by antibodies in rats. The researchers found that rats receiving Ig survived longer and had less damage to their transplanted kidneys compared to those receiving saline. Specifically, the Ig group showed a significant reduction in factors related to inflammation and antibody levels, which are crucial for preventing kidney damage. Who this helps: This helps kidney transplant patients and doctors managing antibody-related rejections.

Plain English
This study looked at a specific case of a 68-year-old woman with a type of kidney cancer who had treatment with immune checkpoint inhibitors. After she received radiation therapy for a painful back lesion, not only did the lesion shrink, but nearby cancerous lymph nodes also reduced in size—potentially due to a "bystander" effect of the immune therapy. This matters because it suggests that combining radiation with immune treatments could improve outcomes for certain patients with aggressive forms of cancer. Who this helps: This helps patients with advanced urothelial carcinoma and their doctors by providing new treatment options.

Plain English
This study looked at kidney biopsies from 9,004 transplant patients to understand the presence of extra blood vessels (called polar vasculosis) in kidneys that are not affected by diabetes. They found that polar vasculosis was present in 186 cases, and patients with polar vasculosis had higher blood pressure and higher levels of the immunosuppressant drug tacrolimus compared to those without it. This matters because it indicates that polar vasculosis could be a sign of toxicity from the medication used to prevent organ rejection in nondiabetic kidney transplant patients. Who this helps: This information helps doctors manage the treatment of nondiabetic kidney transplant patients.

Plain English
This study looked at a 6-year-old boy who had a kidney transplant and later developed a rare type of rejection where antibodies built up in the kidney tissue. Five years after the transplant, a biopsy showed clear signs of chronic rejection, including linear deposits of IgG antibodies on the tiny blood vessels in the kidneys. This finding matters because it highlights the complex nature of kidney transplant rejections and suggests that certain non-HLA antibodies could play a role in this process, which could lead to better understanding and treatment options. Who this helps: This research benefits doctors and kidney transplant patients, especially children facing similar issues.